The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Merrimack; Newlink Genetics; Pfizer
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Lilly (Inst); Newlink Genetics (Inst); Precision Biologics (Inst); Verastem (Inst)
The prognostic value of baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV.
 
Andrea Wang-Gillam
No Relationships to Disclose
 
Li-Tzong Chen
Consulting or Advisory Role - Five Prime Therapeutics; Lilly; Merrimack; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SynCoreBio; TTY Biopharm
Research Funding - GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Polaris (Inst); TTY Biopharm (Inst)
Patents, Royalties, Other Intellectual Property - Anti-alpha enolase ENO-1 monoclonal antibody/HuniLife
 
Chung-Pin Li
No Relationships to Disclose
 
Gyorgy Bodoky
Consulting or Advisory Role - Bayer; Ipsen; Janssen; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Janssen; Lilly; Novartis; Pfizer; Roche
 
Andrew Dean
Honoraria - Specialised Therapeutics
Consulting or Advisory Role - Baxalta; Celgene
 
Kyung-Hun Lee
No Relationships to Disclose
 
David Cunningham
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Sanofi (Inst)
 
Richard Hubner
Consulting or Advisory Role - Baxalta; BTG; Celgene
Speakers' Bureau - Abbott; Ipsen
Travel, Accommodations, Expenses - Celgene
 
Fadi S. Braiteh
Stock and Other Ownership Interests - Agios; Bristol-Myers Squibb; Clovis Oncology; Insys Therapeutics; Tesaro
Honoraria - Abbott Nutrition; Amgen; ARIAD; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; HERON; Incyte; Insys Therapeutics; Insys Therapeutics; Ipsen; Lexicon; Lilly; Taiho Pharmaceutical
Consulting or Advisory Role - Ambry Genetics; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Incyte; Insys Therapeutics; Ipsen; Ipsen; Lexicon; Lilly; Merck; Merrimack; Pfizer; Regeneron; Sanofi
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Incyte; Insys Therapeutics; Ipsen; Lilly; Merck; Merck; Merrimack; Pfizer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bayer; Bayer/Onyx; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Exelixis; HERON; Incyte; Insys Therapeutics; Ipsen; Lexicon; Merrimack; Novartis; Pfizer; Regeneron; Roche/Genentech; Sanofi; Taiho Pharmaceutical; Tesaro
 
J. Marc Pipas
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
 
Bruce Belanger
Employment - Merrimack
Travel, Accommodations, Expenses - Merrimack
 
Floris A. de Jong
Employment - Baxalta; Baxter; Pharmacyclics; Shire
Stock and Other Ownership Interests - Amgen; Baxalta; Pharmacyclics; Shire
 
Purvi D. Mody
Employment - Clovis Oncology; Merrimack
Stock and Other Ownership Interests - ARIAD
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Anthem Inc; Capella Therapeutics; Cell Therapeutics; CerRx; McKesson; Medtronic; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Honoraria - Celgene
Consulting or Advisory Role - 7 Hills Pharma; AADi; Actinium Pharmaceuticals; Aduro Biotech; Aeglea Biotherapeutics; Alethia Biotherapeutics; Alpha Cancer Technologies; Aptose Biosciences; ARIAD; ARMO BioSciences; Arvinas; Athenex; Bellicum Pharmaceuticals; BeyondSpring Pharmaceuticals; Bicycle Therapeutics; BiolineRx; Biological Dynamics; Bionomics; Boston Biomedical; Bristol-Myers Squibb; CanBas; Cancer Prevention Pharmaceuticals; Cerulean Pharma; CORRONA; CV6 Therapeutics ; CytomX Therapeutics; Daiichi Sankyo; Deciphera; Defined Health; DNAtrix; EMD Serono; Esperance Pharmaceuticals; Evelo Therapeutics; Fate Therapeutics; FibroGen; Five Prime Therapeutics; FORMA Therapeutics; Formula Pharmaceuticals; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Gilead Sciences; HealthCare Pharmaceuticals; Histogen; Horizon Discovery; Horizon Pharma; HUYA Bioscience International; Idera; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Immunophotonics; Innate Pharma; Insys Therapeutics; Intezyne Technologies; Janssen Diagnostics; Jounce Therapeutics; Kalos Therapeutics; Kinex; Kura Oncology; L.E.A.F. Pharmaceuticals; Lantern Pharma; Lilly; Lixte Biotechnology; MBC Pharma; Medical Prognosis Institute; miRNA Therapeutics; Novocure; Oncology Venture; Oncolytics; Oncolyze; Pain Therapeutics; Pfizer; Pharmamab; Phosplatin Therapeutics; Progen; Reflexion Medical; RenovoRx; Samus Therapeutics; Senhwa Biosciences; SOTIO; Strategia Therapeutics; Sumitomo Dainippon; Sun Biopharma; Superlab Far East; Synergene; Systems Imagination; Tavistock Life Sciences; TD2; Tolero Pharmaceuticals; TP Therapeutics; Trovagene; Ventana Medical Systems; Verily; Vertex; Viamet Pharmaceuticals
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Aduro Biotech (Inst); Agios (Inst); ArQule (Inst); Baxalta (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); miRNA Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Strategia (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
 
Jens T. Siveke
Consulting or Advisory Role - Baxalta; Celgene; Lilly; Merrimack
Research Funding - 4SC (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Roche